M
Marc A. Pfeffer
Researcher at Brigham and Women's Hospital
Publications - 815
Citations - 143710
Marc A. Pfeffer is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 166, co-authored 765 publications receiving 133043 citations. Previous affiliations of Marc A. Pfeffer include Partners HealthCare & University of Miami.
Papers
More filters
Journal ArticleDOI
Cases of chikungunya imported into Europe.
Marc A. Pfeffer,T Loescher +1 more
TL;DR: Epidemics of chikungunya fever are currently occurring on several islands in the Indian Ocean: Reunion, Mayotte, Mauritius, and Seychelles.
Journal ArticleDOI
Effect of pravastatin on blood pressure in people with cardiovascular disease
Marcello Tonelli,Frank M. Sacks,Marc A. Pfeffer,F Lopez-Jimenez,Gian S. Jhangri,Gary C. Curhan +5 more
TL;DR: Pravastatin 40 mg daily did not reduce blood pressure in survivors of myocardial infarction without overt hypercholesterolaemia and the adjusted risk of incident systolic hypertension was not reduced.
Journal ArticleDOI
Pulsatile hemodynamics in hypertension.
Gary F. Mitchell,Marc A. Pfeffer +1 more
TL;DR: A better understanding of abnormalities in pulsatile load in hypertension will facilitate risk stratification in and treatment of patients with hypertension.
Journal ArticleDOI
Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease
Natalie A. Bello,Natalie A. Bello,Eldrin F. Lewis,Akshay S. Desai,Inder S. Anand,Henry Krum,John J.V. McMurray,Kurt Olson,Scott D. Solomon,Karl Swedberg,Dirk J. van Veldhuisen,James B. Young,Marc A. Pfeffer +12 more
TL;DR: The use of an erythropoesis‐stimulating agent, darbepoetin alfa (DA), to treat anaemia in patients with diabetes mellitus and chronic kidney disease was associated with a heightened risk of stroke and neutral efficacy in the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT), but this association has not been evaluated in another randomized, placebo‐controlled trial.
Journal ArticleDOI
Acute Decline in Renal Function, Inflammation, and Cardiovascular Risk after an Acute Coronary Syndrome
Lisa Mielniczuk,Marc A. Pfeffer,Eldrin F. Lewis,Michael A. Blazing,James A. de Lemos,Satishkumar Mohanavelu,Jean L. Rouleau,Keith A.A. Fox,Terje R. Pedersen,Robert M. Califf +9 more
TL;DR: CRP is an independent predictor for subsequent decline in renal function and reinforces the idea that inflammation may be related to the pathophysiology of progressive renal disease.